Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
A pilot study to determine the safety of using perioperative panitumumab with EOX
(epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus
and stomach.